Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.33 - $0.65 $15,828 - $31,177
47,966 New
47,966 $23,000
Q1 2023

May 15, 2023

SELL
$0.19 - $0.64 $56,213 - $189,351
-295,861 Reduced 94.91%
15,855 $3,000
Q4 2022

Feb 14, 2023

BUY
$0.49 - $0.57 $122,754 - $142,795
250,519 Added 409.36%
311,716 $165,000
Q3 2022

Nov 14, 2022

SELL
$0.49 - $1.95 $7,194 - $28,631
-14,683 Reduced 19.35%
61,197 $31,000
Q2 2022

Aug 15, 2022

BUY
$0.36 - $1.78 $15,971 - $78,967
44,364 Added 140.77%
75,880 $135,000
Q4 2021

Feb 14, 2022

SELL
$0.91 - $4.16 $30,842 - $140,994
-33,893 Reduced 51.82%
31,516 $28,000
Q3 2021

Nov 15, 2021

BUY
$3.78 - $5.18 $79,716 - $109,241
21,089 Added 47.58%
65,409 $268,000
Q4 2020

Feb 16, 2021

BUY
$4.55 - $7.29 $60,965 - $97,678
13,399 Added 43.33%
44,320 $280,000
Q3 2020

Nov 16, 2020

SELL
$4.22 - $6.04 $1.62 Million - $2.31 Million
-382,941 Reduced 92.53%
30,921 $133,000
Q2 2020

Aug 14, 2020

SELL
$3.76 - $8.01 $778,244 - $1.66 Million
-206,980 Reduced 33.34%
413,862 $2.43 Million
Q1 2020

May 15, 2020

BUY
$3.5 - $8.51 $859,810 - $2.09 Million
245,660 Added 65.48%
620,842 $2.71 Million
Q4 2019

Feb 14, 2020

BUY
$4.52 - $7.91 $358,738 - $627,792
79,367 Added 26.83%
375,182 $2.56 Million
Q3 2019

Nov 14, 2019

BUY
$4.91 - $9.31 $1.18 Million - $2.25 Million
241,251 Added 442.14%
295,815 $1.45 Million
Q2 2019

Aug 14, 2019

BUY
$7.08 - $10.6 $26,896 - $40,269
3,799 Added 7.48%
54,564 $402,000
Q1 2019

May 15, 2019

SELL
$7.67 - $9.96 $182,285 - $236,709
-23,766 Reduced 31.89%
50,765 $0
Q4 2018

Feb 14, 2019

BUY
$6.59 - $11.28 $202,438 - $346,510
30,719 Added 70.12%
74,531 $588,000
Q3 2018

Nov 13, 2018

BUY
$9.35 - $12.44 $274,824 - $365,648
29,393 Added 203.85%
43,812 $0
Q2 2018

Aug 10, 2018

BUY
$9.11 - $28.88 $131,357 - $416,420
14,419 New
14,419 $0

Others Institutions Holding CBIO

# of Institutions
1
Shares Held
215
Call Options Held
0
Put Options Held
0

About CATALYST BIOSCIENCES, INC.


  • Ticker CBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,477,100
  • Description
  • Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...
More about CBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.